Why is there a need to discuss antibody development, and why speak at the European Antibody Congress?
In a recent interview in association with the European Antibody Congress, we posed this question to 4 of our top speakers, and here is what they had to say:
"Antibodies work and are a multi-billion dollar industry with no growth end in sight so ways and means to fully develop antibodies are critical for cost-effective commercialization. The European biomedical arena is a critical world market and speaking at this important Antibody Congress meeting is an excellent opportunity to interact with these leaders and innovators." Mark Glassy, CEO, Nascent Biologics
"I feel that it is important to share our work on the development therapeutic tetravalent antibody inhibitor of PI3K/AKT/mTOR signalling pathway to receive feedback from the delegates and to facilitate discussions on the streamlined approaches to advance novel biologic antibody-like molecules into the clinical use." Alexey Lugovskoy, Senior Director of Therapeutic Design, Merrimack Pharmaceuticals
"Clinically relevant mechanisms of action of and resistance to Mabs are poorly described. A better knowledge will help us design more powerful agents and avoid unnecessary treatments." Charles Dumontet, Co-Director, INSERM
"I think antibody development is time-consuming and costs a lot of money so there is a lot of need for discussion how to do it the best; I have chosen to speak at the European Antibody Congress because it is a very well known conference with a really great programme" Dietmar Reusch, Director Development Characterisation, Hoffmann-La Roche
Want to find out more? Learn about :
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D